At 5.1% CAGR, Europe Balloon Aortic Valvuloplasty Market is Projected to be Worth US$ 74.67 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe balloon aortic valvuloplasty market was valued at US$ 50.34 million in 2023 and is expected to reach US$ 74.67 million by 2031, registering a CAGR of 5.1% from 2023 to 2031. Rising prevalence of aortic valve stenosis and improvements in TAVI combined with research and development are among the critical factors attributed to drive the Europe balloon aortic valvuloplasty market growth.

Heart valve disease (HVD) is a cardiac defect increasingly linked to functional decline, especially in aging individuals. HVD can cause stenosis, regurgitation, or a combination of the two in any of the four valves. As the incidence of HVD prominently increases with aging, it is estimated to affect millions globally in the upcoming years. The narrowing of the aorta can make it difficult for blood to flow from the heart to various parts of the body, resulting in a condition called aortic stenosis. As the heart is under considerable pressure while pumping blood through the constricted aorta, it leads to symptoms such as shortness of breath, chest pain, and fatigue. The high-risk patient populations are inoperable and cannot undergo surgical aortic valve replacement procedures. As per the study titled "Epidemiology of aortic valve stenosis and of aortic valve incompetence (AI)," published in February 2020, a meta-analysis conducted in Europe, the US, and Taiwan found that aortic stenosis had a prevalence rate of 12.4% and severe aortic stenosis reported prevalence rate of 3.4% in patients aged 75 years and over. Aortic stenosis prevalence exponential increases with age, displaying 0.2% in people aged 50-59 years, 1.3% in the 60-69 year group, 3.9% in the 70-79 year group, and 9.8% in people aged 80-89 years. The high prevalence of aortic valve stenosis is surging the demand for balloon aortic valvuloplasty (BAV) devices. BAV is less invasive than conventional open-heart surgery, making it a more attractive option for patients.

According to the research study titled "Uncovering the treatable burden of severe aortic stenosis in the UK," published in 2021 in the open-access journal Open Heart, ~300,000 people have aortic valve stenosis-a potentially deadly heart condition-in the UK. Of the people with aortic stenosis, ~199,000 (68%) reported to have severe aortic stenosis disease.

Transcatheter aortic valve implantation (TAVI), also called transcatheter aortic valve replacement (TAVR), has become a well-established therapeutic option for severe aortic stenosis. BAV is a crucial procedural step during TAVI to predilate the valve in order to enhance transcatheter delivery. TAVI has emerged as a ground?breaking, minimally invasive alternative to traditional open?heart surgery, primarily designed for aged patients initially considered unsuitable for surgical intervention due to severe aortic stenosis. Thus, the growing prevalence of aortic valve stenosis worldwide drives the balloon aortic valvuloplasty market growth.

On the contrary, high cost of procedures hampers the growth of Europe balloon aortic valvuloplasty market.

Based on product type, the Europe balloon aortic valvuloplasty market is bifurcated into non compliant balloons and semi compliant balloons. The non compliant balloons segment held 70.3% market share in 2023, amassing US$ 35.40 million. It is projected to garner US$ 54.03 million by 2031 to register 5.4% CAGR during 2023-2031.

By country, the Europe balloon aortic valvuloplasty market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.8% share of Europe balloon aortic valvuloplasty market in 2023. It was assessed at US$ 14.99 million in 2023 and is likely to hit US$ 22.72 million by 2031, registering a CAGR of 5.3% during 2023-2031.

Key players operating in the Europe balloon aortic valvuloplasty market B Braun SE; TT Medical, Inc.; Balton; Becton Dickinson and Co; Edwards Lifesciences Corp; Balt; Venus MedTech HangZhou Inc; and OSYPKA, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com